Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Reexamination Certificate
2011-03-08
2011-03-08
Ford, Allison M. (Department: 1651)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
C549S409000
Reexamination Certificate
active
07901675
ABSTRACT:
A method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, includes administering a formulation including mitochondrial coenzyme Q10in a subject in need thereof. The formulation includes Hydro-Q Sorb®, which is a complex of coenzyme Q10 and cyclodextrin.
REFERENCES:
patent: 4684520 (1987-08-01), Bertelli
patent: 4892883 (1990-01-01), Chatterjee et al.
patent: 6045826 (2000-04-01), Borowy-Borowski et al.
patent: 6399089 (2002-06-01), Yegorova et al.
patent: 2003/0012774 (2003-01-01), Moldenhauer et al.
patent: 2004/0077591 (2004-04-01), Dangond
patent: 2004/0142859 (2004-07-01), Steffan et al.
patent: 2009/0012175 (2009-01-01), Bacopoulos et al.
patent: WO 03/032921 (2003-04-01), None
patent: WO 03/047511 (2003-06-01), None
Shults, CW et al. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Experimental Neurology. Available online Jun. 11, 2004. 188: 491-494.
Smith, K., Matson, S., Cormier, K., Ryu, H., Hersch, S.M., Ferrante, R.J., Therapeutic effects of high dosage administration of coenzyme Q10 in the R6/2 model of Huntington's Disease. Presented on Oct. 24, 2004, at Society for Neuroscience Meeting, Oct. 23-27, 2004, San Diego, CA.
U.S. Appl. No. 11/058,297, filed Feb. 16, 2005, entitled Method of Ameliorating or Abrogating the Effects of a Neurodegenerative Disorder, such as Huntington's Disease, by Sodium Butyrate Chemotherapy.
Ferrante, RJ et al. Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice. The Journal of Neuroscience, Oct. 15, 2003, 23(28):9418-9427.
Ferrante RJ, Dedeoglu A, Kubilus J, Sugars KL, Rubinsztein DC, Ryu H, Beal MF, Ratan RR (2002b) Therapeutic effects of mithramycin in R6/2 transgenic Huntington's disease mice. SFN Abstr.
Ludolph, AC, Seelig M, Ludolph A, Novitt, P, Allen CN, Spencer PS, Sabri, MJ. 3-Nitropropionic Acid Decreases Cellular Energy Levels and Causes Neuronal Degeneration in Cortical Explants. Neurodegeneration 1:155-161 (1992).
Van Lint C, Emiliani S, Verdin E (1996) The Expression of a Small Fraction of Cellular Genes is Changed in Response to Histone Hyperacetylation. Gene Expr 5:245-253 (1996).
Hathcock, JN, Shao A. Risk assessment for coenzyme Q10 (Ubiquinone). Regulatory Toxicology and Pharmacology 45 (2006) 282-288.
Ikematsu H, Nakamura K, Harashima S, Fujii K, Fukutomi N. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: A double-blind, randomized, placebo-controlled trial. Regulatory Toxicology and Pharmacology 44 (2006) 212-218.
Ferrante, RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, Lu P, Smith K, Browne S, Beal MF, Kristal BS, Stavrovskaya IG, Hewett S, Rubinsztein DC, Langley B, Rata RR. Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease. The Journal of Neuroscience, Nov. 17, 2004. 24(46):10335-10342.
Office Action dated Oct. 16, 2008, in U.S. Appl. No. 11/058,297, filed Feb. 16, 2005.
Feigin A et al. Assesment of Coenzyme Q10Tolerability in Huntington's Disease. Movement Disorders. vol. 11, No. 3, 1996, pp. 321-323.
Shults, CW et al. Absorption, tolerability, and effects on mitochon-drial activity of oral coenzyme Q10in parkinsonian patients. Neurology—vol. 50, Issue 3 (Mar. 1998), pp. 793-795 (3 pages).
Alston, TA, Mela L, Bright HJ (1977) 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc Natl Acad Sci 74: 3767-3771.
Andreassen OA, Ferrante RJ, Huang HM, Dedeoglu A, Park L, Ferrante KL, Kwon J, Borchelt DR, Ross CA, Gibson GE, Beal MF (2001) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann Neurol 50: 112-117.
Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF(2001) Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 12:3371-3374.
Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 7:298-304.
Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181-4192.
Bhalla, US, Ram PT, Iyengar R (2002) MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 297:1018-1023.
Bhalla US, Iyengar R (1999) Emergent properties of networks of biological signaling pathways. Science 283:381-387.
Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 79:1246-1249.
Browne SE, Ferrante RJ, Beal MF (1999) Oxidative stress in Huntington's disease. Brain Pathol 9:147-163.
Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA, 92:7105-7109.
Black AR, Jensen D, Lin SY, Azizkhan JC (1999) Growth/cell cycle regulation of Sp1 phosphorylation. J Biol Chem 274:1207-1215.
Brondello JM, Pouyssegur J, McKenzie FR (1999) Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science. 286:2514-2517.
Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170.
Candido EP, Reeves R, Davie JR (1978) Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 14:105-113.
Cha JH (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23:387-392.
Chatterjee S, Zaman K, Ryu H, Conforto A, Ratan RR (2001) Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol 49:345-354.
Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6: 797-801.
Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ (1995) Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 85:43-49.
Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22:8942-8950.
Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ (2003) Creatine Therapy Provides Neuroprotection After Onset of Clinical Symptoms in Huntington's Disease Transgenic Mice. J Neurochem 85: 1359-1367.
Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D (2002) Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease. Science 296:2238-2243.
Egorin MJ, Yuan ZM, Sentz DL, Plaisance K, Eiseman JL (1999) Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol 43:445-453.
Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 20:4389-97.
Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002a) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22:1592-1599.
Ferrante RJ, Kubilus JK, Lee J, Ryu H, B
Dinesh Agarwal, P.C.
Fernandez Susan E.
Ford Allison M.
U.S. Department of Veterans Affairs
LandOfFree
Method of using coenzyme Q 10 to treat Huntington's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using coenzyme Q 10 to treat Huntington's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using coenzyme Q 10 to treat Huntington's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2639974